Silvant Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Silvant Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,607	Closed	-$560K	–	316
2025 Q3	$560K	Buy	+18,607	New	+$558K	0.02%	162
2022 Q4	–	Sell	-3,362	Closed	-$139K	–	346
2022 Q3	$139K	Hold	3,362	–	–	0.01%	223
2022 Q2	$201K	Hold	3,362	–	–	0.05%	152
2022 Q1	$244K	Hold	3,362	–	–	0.05%	156
2021 Q4	$283K	Sell	3,362 -216	-6%	-$17.6K	0.05%	156
2021 Q3	$323K	Hold	3,578	–	–	0.06%	148
2021 Q2	$341K	Hold	3,578	–	–	0.05%	147
2021 Q1	$407K	Hold	3,578	–	–	0.07%	135
2020 Q4	$495K	Hold	3,578	–	–	0.08%	124
2020 Q3	$294K	Sell	3,578 -992	-22%	-$82.2K	0.06%	149
2020 Q2	$357K	Hold	4,570	–	–	0.06%	130
2020 Q1	$203K	Hold	4,570	–	–	0.04%	152
2019 Q4	$195K	Hold	4,570	–	–	0.04%	183
2019 Q3	$196K	Hold	4,570	–	–	0.04%	175
2019 Q2	$290K	Hold	4,570	–	–	0.05%	161
2019 Q1	$317K	Hold	4,570	–	–	0.06%	149
2018 Q4	$199K	Hold	4,570	–	–	0.04%	177
2018 Q3	$349K	Hold	4,570	–	–	0.04%	150
2018 Q2	$351K	Hold	4,570	–	–	0.04%	147
2018 Q1	$233K	Buy	+4,570	New	+$230K	0.03%	187

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Silvant Capital Management's RARE Position: Q4 2025 in Review

Silvant Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 18,607 shares — an estimated $560K sold.

Silvant Capital Management first reported a position in RARE in Q1 2018 and held it in 20 quarters. The position peaked at $560K in Q3 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Silvant Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Silvant Capital Management sold 18,607 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $560K.
Silvant Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 20 quarters.
Silvant Capital Management's Ultragenyx Pharmaceutical position peaked at $560K in Q3 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Silvant Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.